A retrospective observational study on the efficacy and safety of pegylated recombinant human granulocyte-colony stimulating factor and recombinant human granulocyte-colony stimulating factor in patients with lymphoma.

Abstract

Listen

Translate article

e20066 Background: To evaluate the efficacy and safety of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with lymphoma. Methods: This retrospective study included patients with newly diagnosed lymphoma who received CHOP ± R (cyclophosphamide, doxorubicin, vincristine, prednisone ± rituximab) between January 2014 to October 2018. PEG-rhG-CSF(brand name: jinyouli) was injected subcutaneously once 24-72 hours after chemotherapy as primary prevention. rhG-CSF was used as prevention or treatment. The primary endpoint was the incidence of febrile neutropenia (FN), and the secondary endpoints included the incidence of grade III/IV neutropenia, the incidence of chemotherapy dose adjustment, the incidence of chemotherapy delay, the rate of antibiotics application and safety. Results: 178 patients with lymphoma were included, of which 76 were in the PEG-rhG-CSF group (256 cycles) and 102 were in the rhG-CSF group (336 cycles). The incidence of FN was 1.17% (3/256) in the PEG-rhG-CSF group and 5.95% (20/336) in the rhG-CSF group, P= 0.003. The incidence of grade Ⅲ/Ⅳ neutropenia and chemotherapy delay in the PEG-rhG-CSF group were significantly lower than those in the rhG-CSF group (12.89%[33/256] vs 50.30%[169/336], P < 0.0001; 3.13%[8/256] vs 9.52% [32/336], P= 0.002). However, there was no significant difference between the two groups in the incidence of dose adjustment (6.25% vs 3.57%, P = 0.128) and the rate of antibiotics application (34.77% vs 33.33%, P= 0.715). And there was no significant difference in the incidence of fever, bone pain and fatigue between the two groups. Conclusions: Compared with rhG-CSF, prophylactic use of PEG-rhG-CSF can significantly reduce the incidence of FN, grade III/IV neutropenia and chemotherapy delay in patients with lymphoma with good safety.